Protagenic Therapeutics Inc
PTIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.45M
Close$
$-0.49
142.8% downside
Current Fair Value
142.8% downsideOvervalued by 142.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.45 Million |
|---|---|
| Enterprise Value | $883,992.00 |
| Dividend Yield | $479749712.15 (-) |
| Earnings per Share | $-3.45 |
| Beta | 1.07 |
| Outstanding Shares | 1,810,208 |
Return
| Return on Equity | 316.93% |
|---|---|
| Return on Assets | 261.82% |
| Return on Invested Capital | -420.80% |
Valuation & Multiples
| P/E Ratio | 0.27 |
|---|---|
| PEG | -0.34 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-4.48
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-4.48
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.46%▼ 2.56% |
|---|---|
| Total Invested | $44,387▼ 70.59% |
| Investors Holding | 4▼ 7.00% |
ESG Score
No data
About Protagenic Therapeutics Inc
1 employeesProtagenic Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of novel and naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorder...